Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.

ABSTRACT:

Objective

In this review, we have summarized the pharmacokinetics, pharmacodynamics and adverse effects of imatinib, dasatinib, nilotinib, bosutinib, ponatinib and radotinib with focus on pharmacogenomic studies with clinical end points. We have discussed the key phase 3 trials of tyrosine kinase inhibitors (TKI) comparing with each other, treatment free remission (TFR) and selection of TKI. Upcoming concepts and related trials in the management of chronic myeloid leukemia (CML) along with future directions have been touched upon.

Evidence acquisition

PubMed, Embase, Google, Cochrane library and Medline were searched to identify relevant literature for the review. Clinicaltrial.gov was searched for upcoming data and trials.

Results

There are lot of gap in pharmacokine

SUBMITTER: Pushpam D 

PROVIDER: S-EPMC7214547 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature